(BMEA) – Company Press Releases
-
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
-
Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219
-
Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
-
Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycl
-
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
-
Biomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare Conference
-
Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study (COVALENT-112) with BMF-219
-
Biomea Fusion to Present at the 42nd Annual J.P. Morgan Healthcare Conference
-
Biomea Fusion Presents Achievement of Minimal Residual Disease Negativity (MRD-neg) in First Complete Responder from Ongoing Phase I Study (COVALENT-101) of BMF-219 in Patients with Relapsed or Refrac
-
Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts
-
Biomea Fusion Presents Long-Term Follow-Up Data Showing Improved Glycemic Control after 22 Weeks Off Treatment in Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes in a P
-
Biomea Fusion Presents Long-Term Follow-Up Data Showing Improved Glycemic Control after 22 Weeks Off Treatment in Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes in a P
-
Biomea Fusion to Present Long-Term Follow-Up Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes and Results from Ex-Vivo Human Islet Experiments at the World Con
-
Biomea Fusion to Present Long-Term Follow-Up Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes and Results from Ex-Vivo Human Islet Experiments at the World Con
-
Biomea Fusion Announces Health Canada Clearance of Clinical Trial Application (CTA) for BMF-219 in Type 1 Diabetes
-
Biomea Fusion Announces Acceptance of Three Abstracts for its Novel Menin Inhibitor Highlighting Durable Glycemic Control in Diabetes Patients at the International Conference on Advanced Technologies
-
Biomea Fusion Announces Acceptance of Three Abstracts for its Novel Menin Inhibitor Highlighting Durable Glycemic Control in Diabetes Patients at the International Conference on Advanced Technologies
-
Biomea Fusion Abstract “BMF-219: A Novel Therapeutic Agent to Reestablish Functional Beta Cells and Provide Long-term Glycemic Control" Selected as One of Six Oral Presentations at 21st World Congre
-
Biomea Fusion Abstract “BMF-219: A Novel Therapeutic Agent to Reestablish Functional Beta Cells and Provide Long-term Glycemic Control" Selected as One of Six Oral Presentations at 21st World C
-
Biomea Fusion to Present New Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WC
-
Biomea Fusion to Present New Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease
-
Biomea Fusion Announces Two Poster Presentations at Upcoming ASH Annual Meeting 2023
-
Biomea Fusion Reports Third Quarter 2023 Financial Results and Corporate Highlights
-
Biomea Fusion Announces First Patient Dosed with Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia in Phase I Clinical Trial (COVALENT-103)
-
Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for BMF-219 in Type 1 Diabetes
-
Biomea Fusion Announces FDA and Health Canada Clearance of the Expansion Cohorts of the Ongoing COVALENT-111 Phase II Study
-
Biomea Fusion Announces Appointment of Juan Pablo Frías, M.D. as Chief Medical Officer
-
Biomea Fusion Reports Second Quarter 2023 Financial Results and Corporate Highlights
-
BMF-219 Induces Complete Responses in Target Acute Myeloid Leukemia (AML) Patient Population
-
Biomea Fusion Presents Positive Clinical Data from the Initial Cohorts of the Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes Mellitus at the American Diabetes Associ
-
Biomea Fusion to Present Late Breaking Data from Ongoing Phase II Trial, COVALENT-111, Evaluating BMF-219 in Patients with Type 2 Diabetes at ADA 2023
-
Biomea Fusion Reports First Quarter 2023 Financial Results and Corporate Highlights
-
Biomea Fusion Reports First Quarter 2023 Financial Results and Corporate Highlights
-
Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia
-
Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia
-
Biomea Fusion to Present Late Breaking Data from Ongoing Phase II Trial, COVALENT-111, Evaluating BMF-219 in Patients with Type 2 Diabetes, at the ADA 83rd Scientific Sessions 2023 in June
-
Biomea Fusion to Present Late Breaking Data from Ongoing Phase II Trial, COVALENT-111, Evaluating BMF-219 in Patients with Type 2 Diabetes, at the ADA 83rd Scientific Sessions 2023 in June
-
Biomea Fusion To Present Two Preclinical Posters at the 114th AACR Annual Meeting
-
Biomea Fusion To Present Two Preclinical Posters at the 114th AACR Annual Meeting
-
Biomea Fusion Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
-
Biomea Fusion Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
-
Biomea Fusion Announces Pricing of Upsized Public Offering of Common Stock
-
Biomea Fusion Announces Pricing of Upsized Public Offering of Common Stock
-
Biomea Fusion Announces Proposed Public Offering of Common Stock
-
Biomea Fusion Announces Proposed Public Offering of Common Stock
-
Biomea Fusion Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
-
Biomea Fusion Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
-
Biomea Fusion Announces Positive Data from Initial Cohorts of Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes; 100 mg Cohort 3 Demonstrated an 89% Response Rate and 1
-
Biomea Fusion to Host Conference Call and Webcast to Discuss Initial Phase II Clinical Data for BMF-219 in Subjects with Type 2 Diabetes on March 28th, 2023 at 8:30 a.m. ET
-
Biomea Fusion to Host Conference Call and Webcast to Discuss Initial Phase II Clinical Data for BMF-219 in Subjects with Type 2 Diabetes on March 28th, 2023 at 8:30 a.m. ET
Back to BMEA Stock Lookup
